Lawrence Otto Klein - 23 Jan 2026 Form 4 Insider Report for Oruka Therapeutics, Inc. (ORKA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ORKA
Reported as of: 23 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2026, 17:38:52 UTC
Prior SEC filing: 01 May 2025
Next SEC filing: 17 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein

Key filing fact

Lawrence Otto Klein filed Form 4 for Oruka Therapeutics, Inc. (ORKA) on 23 Jan 2026.

Key facts

This page summarizes Lawrence Otto Klein's Form 4 filing for Oruka Therapeutics, Inc. (ORKA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Jan 2026, 17:38.

Change

Previous filing in this sequence was filed on 01 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001762583 Primary reporting owner

Klein Lawrence Otto

Relationship: Chief Executive Officer, Director
Address: C/O ORUKA THERAPEUTICS, INC., 855 OAK GROVE AVE., SUITE 100, MENLO PARK
Signature: /s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein
Signature date: 23 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORKA transaction

Common Stock

Award

Transaction value: $0
Shares: +76,700
Change %: +9%
Price: $0.000000
Shares after: 929,038
Date: 23 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ORKA transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +306,700
Change %
Price: $0.000000
Shares after: 306,700
Date: 23 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 306,700
Exercise price: $34.39
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day).

Footnote F2

The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.